Literature data, as well as the results of our experimental studies (after the cholinergic anti-inflammatory mechanism-«cholinergic anti-inflammatory pathway»-we established in 1987) allow us to suppose, that n-cholinomimetic (α7nAChRs agonists, nicotine), acetylcholinesterase reversible inhibitor, adrenomimetics (β2ARs agonists) and m-cholinomimetic (m1-cholinomimetics), along with a range of therapeutic measures, in particular, with prescription of antibiotics, can be considered as promising agents for the treatment of sepsis and septic shock. Septicaemia and septic shock are a major public health problem. Every year, around the world, it causes the death of more than a million people. Mortality from sepsis, depending on various factors, ranges from 12 to 60% of all deaths associated with diseases and their complications [1], and there is an increase in the number of cases of sepsis and the mortality rate from it [2]. Sepsis is a clinical syndrome with the development of life-threatening organ dysfunction caused by impaired regulation of response to infection. In septic shock, there is a critical reduction in tissue perfusion; many organs, including lungs, kidneys and liver, can also be